Rivaroxaban

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Anticoagulation in Patients With Venous Thromboembolism and Cancer

Apixaban vs Rivaroxaban vs No Anticoagulant to Prevent EHIT After Great Saphenous Vein Laser Ablation

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

Emulation of the RECORD3 Trial Using Healthcare Claims Data

A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

Thromboprophylaxis in Lower Limb Immobilisation

High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Rivaroxaban in Pediatric Patients With DVT

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis

Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism